Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech's Invitrogen Chooses Not to Commercialize HUPO's Protein-Standard Mixture

Premium

This story originally ran on Oct. 8.

Life Technologies division Invitrogen has decided not to manufacture or sell the protein-standard mixture it developed in collaboration with the Human Proteome Organization.

In the meantime, HUPO is in negotiations with another vendor to commercialize the mixture developed to serve as a benchmark for the mass spectrometry-based proteomics community. Officials declined to identify the vendor.

HUPO first revealed that Invitrogen had chosen not to commercialize the 20-protein mixture at its annual meeting in Toronto last month, saying Invitrogen could not meet the organization's minimum requirement of 95-percent purity without it being cost-prohibitive.

This week, Invitrogen confirmed its decision in an e-mail to ProteoMonitor. Paul Predki, vice president of molecular biology reagents R&D for Life Tech, said the samples and protocols have been transferred to HUPO "so that [HUPO] can support the standards independently."

He did not address why Invitrogen chose to pull out of the agreement, and the company said it would have no further comment.

The protein-standard sample was developed by the two partners to serve as a benchmark by which researchers can measure the performance of their instruments [See PM 07/21/06]. The mixture was also used by HUPO in a study evaluating the ability of laboratories to characterize the proteins in the samples and identify common bottlenecks.

In a study published in May, seven out of 27 labs – 24 research labs and three commercial vendors – were able to identify all 20 proteins [See PM 05/21/09].

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.